Glucagon‐like‐peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association
Clinical Obesity · 2024-08 · 14 (4)
DOI: 10.1111/cob.12676 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Obesity, online erschienen am 23.05.2024. Verfasst von Anthony Nguyen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University Health Network, Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Mendelian Randomization Analysis, Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Suicide, Attempted. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Heart and Stroke Foundation of Canada, CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Glucagon‐like‐peptide 1 receptor agonists (GLP‐1RA) have transformed type 2 diabetes (T2D) and obesity management. Multiple regulatory agencies are investigating reported associations between GLP1‐RA and increased suicide attempts (SA), but observational data may be prone to confounding. Randomised control trials (RCT) of GLP‐1RA were largely undertaken in people at lower risk of SA. Real‐world data suggest semaglutide use associates with reduced suicidal ideation and depression but was under‐powered to statistically assess risk of SA. Mendelian randomisation (MR) leverages genetic instrument(s) to infer potential causal association between an exposure and an outcome. We undertook MR using missense variants in the gene encoding GLP1R that improve glycemia, lower T2D risk and/or lower BMI, to investigate potential causal association between GLP‐1RA and SA. In people of European ancestry, MR did not find evidence genetically proxied GLP1RA increased SA in a general population cohort: (rs10305492, exposure: HbA1c, odds ratio [OR] and 95% confidence interval [CI]: 1.38, 0.41–4.62, p = .60), (rs10305492, exposure: FG, OR 1.27, 0.52–3.13, p = .60) and (rs1042044, exposure BMI, OR 0.30, 0.06–1.48) with concordant results in a multi‐ancestry SA case–control cohort. In conclusion, we did not find MR evidence that increased GLP‐1RA impacts SA. This awaits confirmation with RCT and real‐world data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University Health Network, Toronto, Toronto, Canada.
- Centre for Addiction and Mental Health (CAMH), Toronto, Institute of Medical Science, Department of Psychiatry & Pharmacology, Banting and Best Diabetes Centre (BBDC), University of Toronto, Toronto, Canada.
- Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, Canada.
- Divisions of Epidemiology and Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Förderung
- Heart and Stroke Foundation of Canada
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Nguyen, A., Smith, E., Hashemy, H., Agarwal, S. M., Hahn, M. K., Paterson, A. D., & Dash, S. (2024). Glucagon‐like‐peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association. Clinical Obesity, 14(4). https://doi.org/10.1111/cob.12676
Vancouver
Nguyen A, Smith E, Hashemy H, Agarwal SM, Hahn MK, Paterson AD, et al. Glucagon‐like‐peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association. Clinical Obesity. 2024;14(4). doi:10.1111/cob.12676
BibTeX
@article{Nguyen2024,
author = {Nguyen, Anthony and Smith, Emily and Hashemy, Habiba and Agarwal, Sri Mahavir and Hahn, Margaret K and Paterson, Andrew D and Dash, Satya},
title = {Glucagon‐like‐peptide 1 receptor agonism and attempted suicide: A Mendelian randomisation study to assess a potential causal association},
journal = {Clinical Obesity},
year = {2024},
volume = {14},
number = {4},
doi = {10.1111/cob.12676}
}
EUVIMED